1)Japanese Study Group of Polypoidal Choroidal Vasculopathy:Criteria for diagnosis of polypoidal choroidal vasculopathy. Nippon Ganka Gakkai Zasshi 109:417-427, 2005
2)Koizumi H, Yamagishi T, Yamazaki T et al:Subfoveal choroidal thickness in typical age-related macular degeneration and polypoidal choroidal vasculopathy. Graefes Arch Clin Exp Ophthalmol 249:1123-1128, 2011
3)Warrow DJ, Hoang QV, Freund KB:Pachychoroid pigment epitheliopathy. Retina 33:1659-1672, 2013
4)Pang CE, Freund KB:Pachychoroid neovasculopathy. Retina 35:1-9, 2015
5)Miyake M, Ooto S, Yamashiro K et al:Pachychoroid neovasculopathy and age-related macular degeneration. Sci Rep 5:16204, 2015
6)Inoue M, Balaratnasingam C, Freund KB:Optical coherence tomography angiography of polypoidal choroidal vasculopathy and polypoidal choroidal neovascularization. Retina 35:2265-2274, 2015
7)Takahashi K, Ogura Y, Ishibashi T et al:Treatment guidelines for age-related macular degeneration. Nippon Ganka Gakkai Zasshi 116:1150-1155, 2012
8)Yamamoto A, Okada AA, Kano M et al:One-year results of intravitreal aflibercept for polypoidal choroidal vasculopathy. Ophthalmology 122:1866-1872, 2015
9)Maruko I, Iida T, Sugano Y et al:Subfoveal retinal and choroidal thickness after verteporfin photodynamic therapy for polypoidal choroidal vasculopathy. Am J Ophthalmol 151:594-603, 2011
10)Koizumi H, Kano M, Yamamoto A et al:Subfoveal choroidal thickness during aflibercept therapy for neovascular age-related macular degeneration:twelve-month results. Ophthalmology 123:617-624, 2016
11)Yamazaki T, Koizumi H, Yamagishi T et al:Subfoveal choroidal thickness after ranibizumab therapy for neovascular age-related macular degeneration:12-month results. Ophthalmology 119:1621-1627, 2012
12)Koizumi H:Polypoidal choroidal vasculopathy:new observations and therapeutic implications. Nippon Ganka Gakkai Zasshi 118:927-942, 2014